Meningococcal Carriage in Children with Atypical Hemolytic Uremic Syndrome Receiving Eculizumab Therapy

• Главные авторы: Asli Kavaz Tufan (Автор), Fatma Ozak Batibay (Автор), Gulsah Kaya Aksoy (Автор), Bora Gulhan (Автор), Beltinge Demircioglu Kilic (Автор), Ismail Dursun (Автор), Bahar Buyukkaragoz (Автор), Aysun Caltik Yilmaz (Автор), Hulya Nalcacioglu (Автор), Tulay Becerir (Автор), Nuran Cetin (Автор), Kubra Celegen (Автор), Meltem Dinleyici (Автор), Mucahit Kaya (Автор), Omer Kilic (Автор), Ener Cagri Dinleyici (Автор)
• Формат: ‌
• Опубликовано: MDPI AG, 2024-09-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Background/Objectives: Eculizumab is a first-line treatment for atypical hemolytic uremic syndrome (aHUS), and patients undergoing eculizumab therapy may become more susceptible to infection caused by <i>Neisseria meningitidis</i> (<i>Nm</i>). While meningococcal vaccination...